Text Size
Trial record 8 of 38 for:    " May 14, 2008":" June 13, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Previous Study | Return to List | Next Study

Preventing HIV/Aids in Drug Abusing Youth

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Oregon Research Institute
ClinicalTrials.gov Identifier:
NCT00680719
First received: May 16, 2008
Last updated: June 4, 2012
Last verified: June 2012
History of Changes
  Purpose

This project involves two studies focusing on the engagement and treatment of adolescents diagnosed with substance use disorders. Study 1 will evaluate a promising parent-based engagement intervention, Community Reinforcement Training, designed to facilitate the entry of resistant drug-abusing adolescents in treatment. The approach will be compared with an Engagement As Usual intervention condition. Study 2 involves a controlled clinical trial evaluating the efficacy of an HIV/AIDS prevention intervention embedded in family-based drug abuse treatment for reducing HIV/AIDS risk behaviors and substance use. Adolescents who are successfully engaged in treatment through Study 1 will be randomly assigned to receive either family therapy alone or family therapy with the integrated HIV/AIDS prevention intervention. Both studies are being conducted in Portland, Oregon.


Condition Intervention Phase
HIV Infections
 Behavioral: IBFT /HIV prevention
Behavioral: IBFT
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Preventing HIV/Aids in Tx-Resistant Drug-Abusing Youth

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Oregon Research Institute:

Primary Outcome Measures:
  • Changes in adolescent's substance use. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in HIV risk behaviors. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 135
Study Start Date: June 2004
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Family Therapy plus HIV prevention
 Behavioral: IBFT /HIV prevention
Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
Active Comparator: 2
Family Therapy only.
 Behavioral: IBFT
Integrated Behavioral and Family Therapy (IBFT).

  Eligibility

Ages Eligible for Study:   15 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Parents have an adolescent in the ages of 15-20 years.
  • Have had contact with the adolescent on at least 40% of the past 90 days.
  • Have some knowledge or evidence that the adolescent would meet DSM-IV diagnostic criteria for a substance abuse disorder.
  • Adolescent has explicitly refused to attend any intake or therapy sessions.
  • All parents' efforts to enter adolescent into treatment have failed, despite therapist's assistance.
  • Residence in Portland vicinity.
  • Sufficient residential stability to permit probable contact at follow-up. (e.g. not homeless at time of intake)

Exclusion Criteria:

  • Evidence of psychotic or organic state of sufficient severity to interfere with understanding of study instruments and procedures.
  • Adolescent has received residential drug treatment longer than a 2-week period in the past 90 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00680719

Locations
United States, Oregon
Oregon Research Institute Center for Family and Adolescent Research
Portland, Oregon, United States, 97205
Sponsors and Collaborators
Oregon Research Institute
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Holly B Waldron, Ph.D. Oregon Research Institute
  More Information

No publications provided

Responsible Party: Oregon Research Institute
ClinicalTrials.gov Identifier: NCT00680719     History of Changes
Other Study ID Numbers: DA17023
Study First Received: May 16, 2008
Last Updated: June 4, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Oregon Research Institute:
substance abuse
HIV risk
Behavior and Mental Disorders
HIV Seronegativity

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on May 21, 2013